NCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting